Literature DB >> 2967810

In-vitro teicoplanin-resistance in coagulase-negative staphylococci from patients with endocarditis and from a cardiac surgery unit.

E P Moore1, D C Speller.   

Abstract

Among 31 strains of coagulase-negative staphylococcus (CNS) causing endocarditis in individual patients, 16 had MIC of teicoplanin greater than or equal to 8 mg/l (MIC50, 8; MIC90, 8; MIC range, 0.5-32 mg/l); and 24 had MBC greater than or equal to 16 mg/l (MBC50, 32; MBC90, 64; MBC range, 4-128 mg/l). Greater sensitivity was shown to vancomycin (MIC50, 2; MIC90, 4; MIC range, 1-8 mg/l; MBC50, 2; MBC90, 4; MBC range, 0.5-8 mg/l). Teicoplanin-resistant CNS (MIC, greater than or equal to 8 mg/l) were detected in the anterior nares of two of three patients and six of nine staff, and in the air, of a cardiac surgery unit, and in other series of CNS of clinical origin. The results of in-vitro sensitivity testing of CNS to teicoplanin are dependent on the media and conditions used, and their clinical significance has not been determined. Nevertheless, the findings reported here put in question the use of teicoplanin alone as prophylaxis during valve replacement surgery.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2967810     DOI: 10.1093/jac/21.4.417

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

Authors:  F Brunet; G Vedel; F Dreyfus; J F Vaxelaire; T Giraud; B Schremmer; J F Monsallier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

3.  Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs.

Authors:  G Vedel; M Leruez; F Lémann; E Hraoui; D Ratovohery
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

4.  Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.

Authors:  F W Goldstein; A Coutrot; A Sieffer; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Management of serious staphylococcal infections in the outpatient setting.

Authors:  W Graninger; E Presterl; C Wenisch; E Schwameis; S Breyer; T Vukovich
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 6.  Structure, biochemistry and mechanism of action of glycopeptide antibiotics.

Authors:  P E Reynolds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-11       Impact factor: 3.267

7.  In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  J G Barr; E T Smyth; G M Hogg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.